Scotland Approves First CLDN18.2-Targeted Therapy for Advanced Gastric and GEJ Cancer

Scotland has become the first nation in the UK to approve a novel targeted therapy for advanced gastric and gastroesophageal junction (GEJ) cancer. The approval expands treatment options for patients whose tumors do not express HER2, a protein often overexpressed in certain cancers.

What is CLDN18.2?

claudin 18.2 (CLDN18.2) is a protein highly expressed on the surface of gastric cancer cells, but typically absent in normal adult tissues. This makes it an attractive target for cancer therapies, as drugs designed to bind to CLDN18.2 can selectively attack cancer cells while minimizing harm to healthy cells. Cancer Research UK provides thorough data on stomach cancer and its characteristics.

The Approved Therapy: Futibatinib

The approved therapy is futibatinib, a highly selective, orally available tyrosine kinase inhibitor (TKI) that specifically targets CLDN18.2. the Scottish Medicines Consortium (SMC) accepted futibatinib for use within NHS Scotland,marking a meaningful step forward in the treatment of this challenging cancer. The Scottish Medicines Consortium announced the acceptance on January 29, 2024.

Who Will Benefit?

this approval is specifically for patients with locally advanced or metastatic gastric or GEJ adenocarcinoma who have progressed after prior-line chemotherapy. Crucially, the cancer must not be HER2-positive. HER2-targeted therapies are effective for a subset of gastric cancers, but many patients do not have this target. futibatinib offers a new option for thes patients.

Clinical Trial Data Supporting the Approval

The approval is based on data from the Phase 2 FOAKUS trial, which demonstrated promising efficacy and a manageable safety profile for futibatinib in patients with CLDN18.2-positive advanced gastric and GEJ cancer. The trial showed a statistically significant objective response rate (ORR) and progression-free survival (PFS) in heavily pre-treated patients. Takeda, the manufacturer of futibatinib, has released detailed information about the trial results.

What Does This Meen for Patients?

Previously, treatment options for HER2-negative advanced gastric cancer after chemotherapy were limited. This approval provides a new,targeted approach that may improve outcomes and quality of life for eligible patients. The availability of futibatinib represents a significant advancement in personalized cancer medicine.

Potential Side Effects

As with all cancer treatments, futibatinib can cause side effects. Common side effects observed in clinical trials included hyperbilirubinemia (increased bilirubin levels), diarrhea, and fatigue. Healthcare professionals will carefully monitor patients for side effects and manage them appropriately.

Key Takeaways

• Scotland is the first UK nation to approve futibatinib, a CLDN18.2-targeted therapy.
• The therapy is for patients with advanced gastric or GEJ cancer who are HER2-negative and have progressed after chemotherapy.
• Futibatinib targets CLDN18.2, a protein highly expressed on gastric cancer cells.
• Approval is based on positive results from the Phase 2 FOAKUS trial.
• This provides a new treatment option for a patient population with limited alternatives.

Source: Medscape News UK